The Fort Worth Press - Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

USD -
AED 3.672503
AFN 64.999811
ALL 82.324126
AMD 360.540277
ANG 1.790403
AOA 918.000169
ARS 1544.939993
AUD 1.47493
AWG 1.8
AZN 1.698924
BAM 1.769883
BBD 2.014669
BDT 124.715381
BGN 1.77347
BHD 0.378283
BIF 3011.021908
BMD 1
BND 1.291151
BOB 11.678099
BRL 5.666297
BSD 1.000231
BTN 94.44641
BWP 14.015512
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.42537
CDF 2315.000184
CHF 0.837958
CLF 0.025469
CLP 1002.376741
CNY 6.67175
CNH 6.673395
COP 3319.97
CRC 449.312832
CUC 1
CUP 24.064952
CVE 100.149904
CZK 22.122964
DJF 178.554905
DKK 6.77912
DOP 60.996961
DZD 137.215041
EGP 53.460841
ERN 15
ETB 164.576405
EUR 0.906405
FJD 2.27435
FKP 0.756889
GBP 0.756398
GEL 2.590269
GGP 0.756889
GHS 11.724953
GIP 0.756889
GMD 74.000357
GNF 8883.748356
GTQ 7.646644
GYD 209.264655
HKD 7.84526
HNL 26.963306
HRK 6.831965
HTG 131.491813
HUF 330.867502
IDR 18235.4
ILS 3.216696
IMP 0.756889
INR 94.245498
IQD 1520.116116
IRR 1913737.498051
ISK 123.929951
JEP 0.756889
JMD 158.434254
JOD 0.709004
JPY 159.657496
KES 130.049851
KGS 87.435501
KHR 4080.00019
KMF 447.000297
KPW 900.00035
KRW 1335.484966
KWD 0.31147
KYD 0.835579
KZT 446.945163
LAK 22570.87132
LBP 89792.715562
LKR 333.505692
LRD 170.463102
LSL 16.951422
LTL 2.952741
LVL 0.60489
LYD 6.463464
MAD 9.936862
MDL 18.213816
MGA 4555.721867
MKD 55.830725
MMK 2100.274506
MNT 3605.662913
MOP 8.103688
MRU 40.552456
MUR 47.619801
MVR 15.400731
MWK 1738.739965
MXN 18.526497
MYR 4.086105
MZN 63.902977
NAD 16.951422
NGN 1343.570244
NIO 36.90298
NOK 10.16413
NPR 151.114437
NZD 1.808483
OMR 0.385095
PAB 1.000231
PEN 3.411802
PGK 4.575679
PHP 63.960117
PKR 277.274459
PLN 3.994115
PYG 6207.891986
QAR 3.64425
RON 4.851895
RSD 106.558993
RUB 82.765228
RWF 1483.467138
SAR 3.82571
SBD 8.097697
SCR 13.874904
SDG 601.490624
SEK 10.06572
SGD 1.287102
SHP 0.752984
SLE 23.050404
SLL 20969.503664
SOS 573.048487
SRD 37.490144
STD 20697.981008
STN 22.225246
SVC 8.773983
SYP 13002.000337
SZL 16.946523
THB 33.874985
TJS 9.249966
TMT 3.5
TND 3.008497
TOP 2.40776
TRY 50.346255
TTD 6.806368
TWD 32.891398
TZS 2655.145825
UAH 45.588969
UGX 4131.053487
UYU 40.541335
UZS 12057.876355
VES 912.87925
VND 25725.5
VUV 120.320092
WST 2.810586
XAF 594.562705
XAG 0.020459
XAU 0.00025782798
XCD 2.70255
XCG 1.807139
XDR 0.707052
XOF 594.562705
XPF 108.324971
YER 236.550281
ZAR 16.93755
ZMK 9001.216069
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.080549
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today provided an update on its two patent applications, originally filed as provisional patent applications with the U.S. Patent and Trademark Office ("USPTO") on March 31, 2023 and October 2, 2024, respectively, pertaining to Oral Mucosal Formulations of Aspirin that utilize Aspire's fast acting formulation.

Text size:

A provisional patent application is a critical step on the road to commercial viability. As the climate for intellectual property rights becomes increasingly competitive, a provisional patent application establishes an early effective filing date for any subject matter disclosed in the provisional application and allows the patent applicant or a licensee to ascribe the phrase "patent pending" to any product or method covered by the provisional application.

"The filing of these patent applications for our innovative drug delivery platform marks another important step in strengthening our intellectual property portfolio and potentially offers a rapid, cost-effective, and scalable way to produce a new therapeutic sublingual form of aspirin," commented Kraig Higginson, Chief Executive Officer of Aspire. "We believe that our technology has the potential to transform sublingual drug delivery by improving the efficacy and safety of a wide range of medications. We are committed to advancing the therapeutic applications of this innovative technology platform to address critical healthcare challenges and improve patient outcomes."

The Company believes its patent pending technology is groundbreaking because it offers significant advantages over existing oral formulations of numerous prescription and non-prescription products due to its new mechanism of action (absorption pathway) which allows for rapid sublingual absorption. The benefits of "rapid absorption" are to provide nearly instant treatment impact and high dose absorption. The Company's patent pending delivery system includes components specifically formulated to allow rapid sublingual absorption of drugs into the blood stream, thus by-passing the gastrointestinal tract, and potentially provide an improved treatment outcome.

Aspire's lead product candidate, high-dose sublingual aspirin, is a granular or powder formulation of a soluble, Ph neutral, fast-acting aspirin designed to address cardiology emergencies and pain management. Aspire believes the benefits of "rapid absorption" aspirin include the potential to quickly address cardiac incidents; allow high dose absorption for pain management including fast headache relief, post-surgery, cancer pain management, and general pain relief.

Aspirin Product Development and Clinical Trials

  • Initiate bioavailability study in healthy human volunteers approximately April 2025

  • Pre-IND meeting with the FDA in the second quarter of 2025

  • Commence final clinical trial to evaluate the pharmacodynamic effect of a single dose of our aspirin product on platelet inhibition compared to that of standard oral aspirin in Q2 2025.

  • Request "fast track" approval on its NDA for the high dose aspirin product to the FDA.

  • Clinical trials in Fall 2025 of our low dose sublingually administered aspirin for preventative care.

  • High dose sublingually administered aspirin for pain relief (rheumatological and other pain). Building on previous clinical trial as set forth above, we anticipate seeking FDA approval, through an NDA, in the latter part of 2025.

Higginson added, "With these critical steps underway, and with new funding, Aspire is committed to achieving key milestones on our path to commercialization."

Aspire believes its platform represents a significant advancement in drug delivery, offering a novel approach to improving the bioavailability of active pharmaceutical ingredients (APIs) and addressing critical challenges in both local and systemic drug delivery. The patent applications underscore Aspire's commitment to securing comprehensive intellectual property protection for its innovative technology, which is designed to improve health and drug delivery.

Key Potential Features of the Aspire Platform

  • Fast Acting - Powder-form medication developed using our patent-pending technology enters the bloodstream in a fraction of the time required by swallowed tablets and capsules

  • Water Soluble - Our products dissolve easily under the tongue

  • Dosage Management - Drugs do not pass through the liver and are not metabolized in the gastric system like oral products

  • Bypasses the Digestive Tract - Eliminates adverse reactions in the gastrointestinal tract

  • Easy to use - those who have difficulty swallowing pills can easily use our products, even those who are unconscious can receive life-saving medication quickly

About Aspire Biopharma, Inc.

Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

TraDigital IR
Kevin McGrath
+1-646-418-7002
[email protected]

SOURCE: Aspire Biopharma Holdings, Inc.



View the original press release on ACCESS Newswire

N.Patterson--TFWP